Solving biologic delivery
Our proprietary sphingolipid platform enables large therapeutic molecules to cross biological barriers in the body, facilitating unprecedented absorption and delivery. We are pursuing a range of clinical applications, including oral formulations of traditionally injectable biologics for metabolic and autoimmune diseases.
Harnessing a natural pathway
Building on discoveries from the Lencer Lab, our technology harnesses a natural process of cellular transport. With it, we can achieve greater degrees of bioavailability and biodistribution without disruption to the body’s natural barriers.
We are actively seeking partners to develop biologic medicines for a range of chronic diseases, including metabolic, autoimmune, and neurodegenerative disorders. Our interests include peptide, protein, and oligonucleotide therapeutics.
Transforming chronic disease treatment through a new approach to biologic medicines